Suven to present results from Phase-2a study of Ropanicant at Neuroscience 2024 EP News Bureau Oct 3, 2024 Suven plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to…
Suven announces randomisation of first patient in Phase-2 POC clinical trial of Ropanicant… EP News Bureau Feb 6, 2024 The Phase-2 clinical trial of Ropanicant (SUVN-911) is for the treatment of moderate to severe Major Depressive Disorder (MDD)…
